The Evolving Field of Biomarker Testing in Solid Tumors

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.